Dr Khanani begins with the GALE study, which demonstrated that pegcetacoplan (PEG) provided benefit in visual function on a ...
A 36-week treatment regimen of pegcetacoplan reduces geographic atrophy growth rate while demonstrating a favorable safety profile.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback